| Dec'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||
Total revenues | |||||||||
295 | 2,156 | 3,091 | 3,233 | 5,653 | 9,041 | 4,961 | 32,733 | 14,709 | 60,930 |
Costs and Expenses: | |||||||||
Costs of goods sold | |||||||||
0 | 613 | 483 | 1,159 | 264 | 338 | 392 | 427 | 419 | 960 |
Costs of license fee and other revenues | |||||||||
- | - | - | - | - | 1,189 | - | 0 | - | - |
Research and development | |||||||||
254,871 | 99,283 | 51,776 | 53,492 | 41,735 | 33,680 | 28,381 | 24,255 | 24,536 | 19,853 |
Sales and marketing | |||||||||
26,459 | 6,822 | 873 | 1,027 | 768 | 1,132 | 826 | 846 | 828 | 834 |
General and administrative | |||||||||
43,803 | 36,485 | 29,109 | 6,563 | 9,102 | 8,281 | 6,154 | 5,762 | 7,116 | 5,348 |
Total costs and expenses | |||||||||
325,133 | 143,203 | 82,241 | 62,241 | 51,872 | 44,621 | 35,754 | 31,291 | 32,900 | 26,997 |
Operating loss | |||||||||
-324,838 | -141,047 | -79,150 | -59,008 | -46,219 | -35,580 | -30,792 | 1,442 | -18,190 | 33,933 |
Fair Value Adjustment of Warrants | |||||||||
0 | 108,636 | 61,074 | 0 | - | - | - | - | - | - |
Adjustment of Warrants Granted for Services | |||||||||
0 | 0 | 7,649 | 0 | - | - | - | - | - | - |
Interest expense | |||||||||
40,337 | 23,255 | 5,480 | 5,480 | 2,090 | - | - | - | - | - |
Arbitration settlement, net | |||||||||
- | - | - | - | - | - | 16,739 | 0 | 0 | - |
Insurance proceeds received | |||||||||
- | - | - | - | - | - | 2,637 | 0 | 279 | - |
Qualifying Therapeutic Discovery Project Program | |||||||||
- | - | - | - | - | - | - | - | 2,888 | - |
Gain on sales and redemptions of auction rate securities | |||||||||
- | - | - | - | - | - | - | - | 454 | 915 |
Interest and other income | |||||||||
7,856 | 5,493 | 431 | 338 | 245 | 55 | 10 | 18 | 239 | 788 |
Loss on induced exchanges of debt | |||||||||
0 | -13,005 | 0 | 0 | - | - | - | - | - | - |
Other financing expenses | |||||||||
0 | 0 | 347 | 0 | - | - | - | - | - | - |
Insurance reimbursement | |||||||||
0 | 6,638 | 0 | 0 | - | - | - | - | - | - |
Foreign currency transaction gain, net | |||||||||
0 | 81 | 23 | -40 | -1 | 0 | -37 | 13 | 26 | 129 |
Loss before income tax | |||||||||
-357,319 | -273,731 | -153,246 | -64,190 | -48,065 | -35,523 | -11,442 | 1,474 | -14,302 | 35,767 |
Income tax expense | |||||||||
0 | 156 | 20 | -5,054 | 58 | 7 | 44 | 209 | 109 | -1,228 |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | |||||||||
-357,319 | -273,887 | -153,266 | -59,136 | -48,123 | -35,531 | -11,486 | 1,264 | -14,412 | 36,996 |
Net loss attributable to noncontrolling interest | |||||||||
-129 | -50 | -60 | -99 | -121 | -105 | -104 | -113 | -173 | - |
Net loss attributable to Immunomedics, Inc. stockholders | |||||||||
-357,190 | -273,837 | -153,206 | -59,037 | -48,002 | -35,425 | -11,381 | 1,378 | -14,238 | 36,996 |
Loss per common share attributable to Immunomedics, Inc. stockholders: | |||||||||
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in usd per share) | |||||||||
-1.84 | -1.78 | -1.47 | -0.62 | -0.51 | -0.42 | -0.15 | - | - | - |
Basic | |||||||||
- | - | - | - | - | - | - | 0.02 | -0.19 | 0.49 |
Diluted | |||||||||
- | - | - | - | - | - | - | 0.02 | -0.19 | 0.49 |
Weighted average shares used to calculate loss per common share: | |||||||||
Weighted average shares used to calculated loss per common share (basic and diluted) (in shares) | |||||||||
193,617 | 153,475 | 104,536 | 94,770 | 93,314 | 84,631 | 78,040 | - | - | - |
Basic | |||||||||
- | - | - | - | - | - | - | 75,481 | 75,313 | 75,200 |
Diluted | |||||||||
- | - | - | - | - | - | - | 76,174 | 75,313 | 75,994 |
Other comprehensive loss, net of tax: | |||||||||
Foreign currency translation adjustments | |||||||||
174 | -105 | -62 | 1 | -434 | 100 | 81 | -314 | 262 | -297 |
Consolidated net (loss) income | |||||||||
-357,319 | -273,887 | -153,266 | -59,136 | -48,123 | - | - | - | - | - |
Unrealized loss on securities available for sale | |||||||||
-391 | 55 | -109 | 28 | 11 | -0 | - | 0 | -208 | 208 |
Other Comprehensive Income (Loss), Net of Tax | |||||||||
-217 | -50 | -171 | 29 | -422 | 100 | 81 | -314 | 53 | -88 |
Net comprehensive (loss) income | |||||||||
- | - | - | - | - | - | - | -950 | 14,358 | -36,907 |
Comprehensive loss | |||||||||
-357,536 | -273,937 | -153,437 | -59,107 | -48,546 | -35,431 | -11,404 | 113 | 173 | - |
Comprehensive loss attributable to noncontrolling interest | |||||||||
-129 | -50 | -60 | -99 | -121 | -105 | -104 | - | - | - |
Comprehensive loss attributable to Immunomedics, Inc. stockholders | |||||||||
-357,407 | -273,887 | -153,377 | -59,008 | -48,425 | -35,325 | -11,299 | 1,063 | -14,184 | 36,907 |
Product sales | |||||||||
Revenues | |||||||||
0 | 1,501 | 2,443 | 2,261 | 2,648 | 3,140 | 2,991 | 3,517 | 3,607 | 3,146 |
License fee and other revenues | |||||||||
Revenues | |||||||||
295 | 330 | 284 | 387 | 1,250 | 4,623 | 126 | 28,418 | 10,126 | 55,685 |
Research and development | |||||||||
Revenues | |||||||||
0 | 325 | 364 | 585 | 1,754 | 1,277 | 1,844 | 798 | 975 | 2,098 |